Breast Cancer Research and Treatment

, Volume 110, Issue 2, pp 273–281 | Cite as

Differential gene expression profile in breast cancer-derived stromal fibroblasts

  • Christian F. Singer
  • Daphne Gschwantler-Kaulich
  • Anneliese Fink-Retter
  • Cornelia Haas
  • Gernot Hudelist
  • Klaus Czerwenka
  • Ernst Kubista
Preclinical Study



Breast cancer is characterized by malignant transformation of epithelial cells, but stromal cells also play an important role in tumorigenesis. While tumor-derived fibroblasts display unique phenotypic properties, it is unclear whether they also represent are a specific subpopulation.

Materials and Methods

Stromal fibroblasts deriving from malignant tissue of 10 women with invasive breast cancer, and from normal breast tissue of 10 women with benign breast disorders, were subjected to differential complementary DNA Microarray Analysis by using a 2,400 gene cDNA array. Individual gene expression pattern were confirmed by RT-PCR.


In a cDNA array that allows to analyze the differential gene expression of more than 2,400 genes, the mRNA expression of 135 genes were increased more than 2 fold in fibroblasts from malignant breast tumors. The majority of these genes encode tumor-promoting cytokines, transcription factors and cell-matrix associated proteins. The mRNA expression of 110 genes decreased to less than 0.5 fold. The remaining 2,155 genes were not significantly altered. RT-PCR performed on individual biopsies from breast cancer and normal breast tissues confirmed the validity of the pooled gene expression signature.


Breast cancer-derived stromal fibroblasts show a distinctive gene expression pattern that differentiates them from normal breast stroma. Our observation of increased expression of tumor promotion-associated genes even in the absence of adjacent malignant epithelium suggests that tumor stroma is comprised of a fibroblastic subpopulation that provides for a microenvironment which supports tumor growth and invasion.


Breast cancer Gene expression profile Stromal fibroblasts 



This study was supported by a grant from the Foundation for Breast Health, by a grant from the Austrian Society for Endocrinological Oncology, by a grant from Amgen Inc. and Ebewe Inc., and by a grant from Medizinisch-Wissenschaftlicher Fonds des Bürgermeisters der Bundeshauptstadt Wien.


  1. 1.
    Wiseman BS, Werb Z (2002) Stromal effects on mammary gland development and breast cancer. Science 296:1046–1049PubMedCrossRefGoogle Scholar
  2. 2.
    Bonnette SG, Hadsell SL (2001) Targeted disruption of the IGF-I receptor gene decreases cellular proliferation in mammary terminal end buds. Endocrinology 142:4937–4945PubMedCrossRefGoogle Scholar
  3. 3.
    Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM, Egger M (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363:1346–1353PubMedCrossRefGoogle Scholar
  4. 4.
    Kucab JE, Dunn SE (2003) Role of IGF-1R in mediating breast cancer invasion and metastasis. Breast Dis 17:41–47PubMedGoogle Scholar
  5. 5.
    Derynck R, Akhurst JR, Balmain A (2001) TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29:117–129PubMedCrossRefGoogle Scholar
  6. 6.
    Kaklamani V, Pasche B (2005) Transforming growth factor beta and breast cancer. Cancer Treat Res 126:129–156PubMedCrossRefGoogle Scholar
  7. 7.
    Duffy MJ, Maguire TM, Hill A, McDermott E, O’Higgins N (2000) Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2(4):252–257PubMedCrossRefGoogle Scholar
  8. 8.
    Mercurio AM, Bachelder RE, Chung J, O’Connor KL, Rabinovitz I, Shaw LM, Tani T (2001) Integrin laminin receptors and breast carcinoma progression. J Mammary Gland Biol Neoplasia 6(3):299–309PubMedCrossRefGoogle Scholar
  9. 9.
    Torricelli C, Fortino V, Capurro E, Sacchi G, Ponzo P, Pacini A, Muscettola M, Maioli E (2006) Role of PTHrp and PTHrp-engaged pathways in MCF-7 cells migration/invasion. Matrix Biol 25(2):104–111PubMedCrossRefGoogle Scholar
  10. 10.
    Barcellos-Hoff MH, Medina D (2005) New highlights on stroma-epithelial interactions in breast cancer. Breast Cancer Res 7(1):33–36PubMedCrossRefGoogle Scholar
  11. 11.
    Kim JB, Stein R, O’Hare MJ (2005) Tumour-stromal interactions in breast cancer: the role of stroma in tumourigenesis. Tumour Biol 26(4):173–185PubMedCrossRefGoogle Scholar
  12. 12.
    Singer C, Rasmussen A, Smith HS, Lippman ME, Lynch HT, Cullen KJ (1995) Malignant breast epithelium selects for insulin-like growth factor II expression in breast stroma: evidence for paracrine function. Cancer Res 55(11):2448–2454PubMedGoogle Scholar
  13. 13.
    Grey AM, Schor AM, Rushton G, Ellis I, Schor SL (1989) Purification of the migration stimulating factor produced by fetal and breast cancer patient fibroblasts.Proc. Natl Acad Sci U S A 86:2438–2442CrossRefGoogle Scholar
  14. 14.
    Zrihan-Licht S, Lim J, Keydar I, Sliwkowski MX, Groopman JE, Avraham H (1997) Association of csk-homologous kinase (CHK) (formerly MATK) with HER-2/ErbB-2 in breast cancer cells. J Biol Chem 272(3):1856–1863PubMedCrossRefGoogle Scholar
  15. 15.
    Gouon-Evans V, Rothenberg ME, Pollard JW (2000) Postnatal mammary gland development requires macrophages and eosinophils. Development 127(11):2269–2282PubMedGoogle Scholar
  16. 16.
    Pollard JW, Hennighausen L (1994) Colony stimulating factor 1 is required for mammary gland development during pregnancy. Proc Natl Acad Sci U S A 91(20):9312–9316PubMedCrossRefGoogle Scholar
  17. 17.
    Lin EY, Nguyen AV, Russell RG, Pollard JW (2001) Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 193(6):727–740PubMedCrossRefGoogle Scholar
  18. 18.
    Castiglioni T, Merino MJ, Elsner B, Lah TT, Sloane BF, Emmert-Buck MR (1994) Immunohistochemical analysis of cathepsins D, B, and L in human breast cancer. Hum Pathol 25(9):857–862PubMedCrossRefGoogle Scholar
  19. 19.
    Harbeck N, Alt U, Berger U, Krüger A, Thomssen C, Jänicke F, Höfler H, Kates RE, Schmitt M (2001) Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy. Clin Cancer Res 7:2757–2764PubMedGoogle Scholar
  20. 20.
    Cook AC, Tuck AB, McCarthy S, Turner JG, Irby RB, Bloom GC, Yeatman TJ, Chambers AF (2005) Osteopontin induces multiple changes in gene expression that reflect the six “hallmarks of cancer” in a model of breast cancer progression. Mol Carcinog 43(4):225–236PubMedCrossRefGoogle Scholar
  21. 21.
    Zohar R, Suzuki N, Suzuki K, Arora P, Glogauer M, McCulloch CA, Sodek J (2000) Intracellular osteopontin is an integral component of the CD44-ERM complex involved in cell migration. J Cell Physiol 184(1):118–130PubMedCrossRefGoogle Scholar
  22. 22.
    Das R, Mahabeleshwar GH, Kundu GC (2003) Osteopontin stimulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells. J Biol Chem 278(31):28593–28606PubMedCrossRefGoogle Scholar
  23. 23.
    Bramwell VH, Doig GS, Tuck AB, Wilson SM, Tonkin KS, Tomiak A, Perera F, Vandenberg TA, Chambers AF (2006) Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res 12(11 Pt 1):3337–3343PubMedCrossRefGoogle Scholar
  24. 24.
    Wakefield LM, Piek E, Bottinger EP (2001) TGF-beta signaling in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia 6(1):67–82PubMedCrossRefGoogle Scholar
  25. 25.
    Muraoka-Cook RS, Dumont N, Arteaga CL (2005) Dual role of transforming growth factor beta in mammary tumorigenesis and metastatic progression. Clin Cancer Res 11(2 Pt 2):937s–943sPubMedGoogle Scholar
  26. 26.
    Nieman MT, Prudoff RS, Johnson KR, Wheelock MJ (1999) N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression. J Cell Biol 147(3):631–644PubMedCrossRefGoogle Scholar
  27. 27.
    Pishvaian MJ, Feltes CM, Thompson P, Bussemakers MJ, Schalken JA, Byers SW (1999) Cadherin-11 is expressed in invasive breast cancer cell lines. Cancer Res 59(4):947–952PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Christian F. Singer
    • 1
  • Daphne Gschwantler-Kaulich
    • 1
  • Anneliese Fink-Retter
    • 1
  • Cornelia Haas
    • 1
  • Gernot Hudelist
    • 1
  • Klaus Czerwenka
    • 2
  • Ernst Kubista
    • 1
  1. 1.Division of Special Gynecology, Department of OB/GYNMedical University of ViennaViennaAustria
  2. 2.Division of Gynecopathology, Department of PathologyMedical University of ViennaViennaAustria

Personalised recommendations